Poster Presented at the 2014 American College of Rheumatology Annual Meeting
|
|
- Chloe Pearson
- 6 years ago
- Views:
Transcription
1 Poster Presented at the 2014 American College of Rheumatology Annual Meeting Anne Winkler 1 James Mossell 2 Edmund MacLaughlin 3 Drew Johnson 4 J. Timothy Harrington 5 1 Winkler Medical Practice LLC, Springfield, MO 2 Arthritis & Osteo Center of South GA, Tifton, GA 3 Edmund L MacLaughlin LLC, Cambridge, MD 4 Crescendo Bioscience, South San Francisco, CA 5 Joiner Associates LLC, Madison, WI 2015 Joiner Associates LLC 1
2 Background/Purpose Population management (PM) is required for reducing the burdens of chronic diseases, including RA. PM depends on standardizing disease activity assessment (DAA) and coordinating care for the entire disease population, as well as for individuals within this context. Our purpose is to implement PM for RA within rheumatology practices by optimizing DAA to define controlled, low, moderate, and high disease activity cohorts; to focus resources on those patients with the highest needs; and to document our delivery of care and outcomes. Methods The Rheumatoid Arthritis Practice Performance (RAPP) Project is a voluntary collaboration of U.S. clinician rheumatologists whose goal is to improve RA management and to document our performance. Most invited to participate are multi-biomarker disease activity test users. To date, 97 physicians from 91 practices have attended quality improvement project kick-off meetings and each has completed a baseline survey regarding DAA and PM processes. Their aggregated responses are reported here. Results Participants represent all regions of the United States and differing practice environments: solo (33), single specialty (35), and multi-specialty group/integrated system practices (20). RA patients managed per rheumatologist derived from practice billing systems varies from 112 to 1800, self-reported patient visits/day from 12 to 80, and new patients/week from 0 to 32. Forty-six % have mid-level providers sharing in RA management, 91% have an electronic medical record (38 different brands), and 35% have RA disease registry capability. DAAs used are highly variable and often multiple. Composite DAA use varies from none (25%), to RAPID3 (39%), DAS28 (18%), CDAI (20%), and SDAI (2%). Disease activity documentation in medical records includes a non-numeric impression (active/controlled) (63%), 0-10 Physician Global (23%), composite score (11%), or other (3%). Conclusion 1. Practices vary in RA population size, office workflows, staffing, and DAAs utilized. 2. Use of composite disease activity measure is limited with the majority documenting a binary, active/controlled clinical impression. 3. PM processes (analytic disease registries and team management) are used infrequently. 4. These results indicate opportunities to improve practice performance and RA disease outcomes in rheumatology practices Joiner Associates LLC 2
3 To understand the disease activity measures and clinical processes being used by clinician rheumatologists prior to their beginning an RA quality improvement collaborative, the Rheumatoid Arthritis Practice Performance (RAPP) Project. Question 1: What is the total number of RA patients you manage? The RAPP Project currently includes 175 rheumatologists from 148 practices managing over 75,000 RA patients. A 12-question baseline web survey was completed by participants prior to their attending a kick-off project advisory board meeting between April 2013 and September Question 2: Identify the clinical data you routinely collect and use to inform your impression of each patient s RA disease activity. Individual responses from 130 respondents were aggregated for this abstract Joiner Associates LLC 3
4 Question 3: How do you document your global assessment of disease activity (Physician Global)? Question 5: How many patient visits do you typically bill per full office day (all patients)? Question 4: What composite disease activity score do you document routinely, if any? Question 6: How many total new patients/consultations do you see per week? 2015 Joiner Associates LLC 4
5 Question 7: Does your practice employ mid-level providers (physician assistants and/or nurse practitioners)? Question 9: Does your office have Electronic Medical Records (EMR)? Question 8: Do your mid-levels share management of RA patients with the rheumatologists? Question 10: What brand of EMR does your office use? 2015 Joiner Associates LLC 5
6 Question 11: Do you have a practice-based database of your RA patients? Question 12: If yes to Question 11, does your database include clinical disease activity data and/or dates of services as a practice management tool? 1. Practices vary in their RA population size, office workflows, staffing, disease activity data, and measures reported. 2. Use of composite disease activity measures is limited with the majority documenting a binary active-versus-controlled impression. 3. Population processes (analytic disease registries, standardized assessment algorithms, and team management) are used infrequently. 4. These results indicate multiple opportunities to improve practice performance and RA disease outcomes. Disclosures A. Winkler, Novartis Pharmaceutical Corporation 2, Janssen Pharmaceutica Product L.P. 2, Pfizer Inc. 2, Janssen Pharmaceutica Product L.P. 8, Crescendo Bioscience 8, Abbott Immunology Pharmaceuticals 8, Genentech and Biogen IDEC Inc. 8, Bristol-Meyers Squibb 8, Glaxo Smith Klein 8, Pfizer Inc. 8, Crescendo Bioscience 5 J. Mossell, Crescendo Bioscience 5, Genentech and Biogen IDEC Inc. 8, Amgen 8, Abbvie 8, Iroko 8, Takeda 8, Crescendo Bioscience 8, Pfizer 8 E. MacLaughlin, Crescendo Bioscience 5 D. Johnson, Crescendo Bioscience 3 J.T. Harrington, Joiner Associates LLC 5, Crescendo Bioscience 5, Pfizer 5 3 Employment (full or part time); 5 Consulting fees or other remuneration (payment); 8 Speaker's bureau 2015 Joiner Associates LLC 6
(Poster presented on Sunday 05 March, 08:50 08:55; 2017 AAD Meeting, Orlando, Florida, USA)
Secukinumab in Psoriasis Patients with Concurrent Psoriatic Arthritis: Patient-Reported Outcomes in the Corrona Psoriasis Registry AB Gottlieb, B Strober, 2 AW Armstrong, 3 JD Greenberg, 4,5 C Karki, 4
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Characterization of Disease Burden, Comorbidities and Use of Patients with Psoriasis at Enrollment: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Ning Guo
More informationDesigning an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients
Designing an Electronic Medical Record-based Clinical Decision Support Tool to Improve CVD Screening in Rheumatoid Arthritis Patients Provided and Certified By Grant Award # 045604 Report Date: March 29,
More informationPsoriasis Disease Severity Affects Patient Satisfaction With Therapy
82 Psoriasis Disease Severity Affects Patient Satisfaction With Therapy Korman NJ 1, Zhao Y 2, Tran MH 2, Lu J 2 (Please see authors affiliations on the last panel) Background Psoriasis is a chronic, immune
More informationKenneth Gordon, 1 Kim A. Papp, 2 Kara Creamer Rice, 3 Mona Trivedi, 3 David H. Collier, 3 Greg Kricorian 3
American Academy of Dermatology 75 th Annual Meeting, Orlando, FL; March 3 7, 2017 Poster 4563 Novel Evaluation of Psoriasis Area and Severity Index (PASI) Data: Distribution of PASI Improvements in a
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Add your company logo here Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 USMD Health System RA Collaborative 2 Medical Group Profile USMD Health System:
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. University of Rochester. Adding Patient Reported Outcome Measures
Best Practices in Managing Patients with Rheumatoid Arthritis Adding Patient Reported Outcome Measures Organizational Profile Strong Memorial Hospital is a large tertiary care center located in Rochester,
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Summit Medical Group. Standardizing Protocols and Educating Providers
Best Practices in Managing Patients with Rheumatoid Arthritis Summit Medical Group Standardizing Protocols and Educating Providers Organizational Profile Summit Medical Group, established in 1929, is the
More informationEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis (UNVEIL Phase IV Study)
4892 Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis ( Phase IV Study) Bruce Strober, MD 1 ; Jerry Bagel, MD 2 ; Mark Lebwohl, MD 3 ; Linda Stein Gold, MD 4 ; J. Mark Jackson,
More informationUniversity of California, San Diego, School of Medicine, La Jolla, CA, USA; 2
2194 Long-term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Psoriatic Arthritis: Results From a Phase III, Randomized, Controlled Trial
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Kelsey-Seybold Clinic. Implementing Evidenced- Based Medicine in the Management of RA
Best Practices in Managing Patients with Rheumatoid Arthritis Implementing Evidenced- Based Medicine in the Management of RA Organizational Profile (KSC) began in 1949 by founder Dr. Mavis P. Kelsey. Modeling
More informationBruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4, Mark Lebwohl 5
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3,
More informationAssociation between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry
4385 Association between disease severity and body mass index in psoriasis patients enrolled in the Corrona Psoriasis Registry Bruce Strober 1, 2, Chitra Karki 3, Marc Mason 3, Jeffrey D Greenberg 3,4,
More informationWho Pays for Personalized Medicine? A Conversation With Industry Insiders. July 15, 2010 Garden Court Hotel, Palo Alto
Who Pays for Personalized Medicine? A Conversation With Industry Insiders July 15, 2010 Garden Court Hotel, Palo Alto Speakers Aidan Toombs, Attorney, Crescendo Bioscience Judy Waltz, Partner and Co-Chair,
More informationThe future of IBD therapeutic research
The future of IBD therapeutic research Jean-Frederic Colombel, MD Director Susan and Leonard Feinstein IBD Clinical Center Icahn School of Medicine, Mount Sinai Hospital New York J-F Colombel has served
More informationImmune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy
Immune-Related Adverse Events (IRAEs) due to Cancer Immunotherapy Philip Mease MD Director, Rheumatology Clinical Research, Swedish- Providence St. Joseph Health Clinical Professor, University of Washington
More informationSymptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission
Symptom Severity, Quality of Life and Work Productivity of US Psoriasis Patients During Periods of Flare and Remission 93 Korman, NJ 1, Zhao, Y 2, Roberts, J 3 Pike, J 3, Lu, J 2, Tran, MH 2 (Please see
More informationKey ASCO Presentations Issue 4, Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM)
Key ASCO Presentations Issue 4, 2010 Effects of Zoledronic Acid on Overall Survival in Newly Diagnosed Multiple Myeloma (MM) For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF
More informationA.K. Gitt, F. Towae, C. Juenger, A. Papp, R. Zahn, U. Zeymer, J. Senges For the STAR-Study-Group Herzzentrum Ludwigshafen, Germany
Impact of Interventional Versus Conservative Approach on 5-Year-Mortality of Patients With Stable Angina and Documented Coronary Artery Disease in Clinical Practice: Results of the STAR-Registry A.K. Gitt,
More informationVectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis?
Vectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis? Ronald F. van Vollenhoven, MD, PhD Jonathan Kay, MD Andrew Laster MD, FACR Eric Sasso, MD Crescendo Bioscience
More information- For Internal Use Only - - Do Not Distribute
Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 Springfield Clinic Rheumatology Jennifer Boyer RN, MBA Carla Osterholt 2 Medical Group Profile Founded in 1939
More informationCritical Pathways in Breast Cancer Treatment
Critical Pathways in Breast Cancer Treatment Faculty Jenny C Chang, MD Paul E Goss, MD, PhD Kathy D Miller, MD Lawrence N Shulman, MD Dennis J Slamon, MD, PhD Andrew Tutt, MB ChB, PhD Editor Neil Love,
More informationFirst-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC)
Key ASCO Presentations Issue 7, 2010 First-Line Erlotinib with or without Chemotherapy for Never or Light Smokers with Advanced Non-Small Cell Lung Cancer (NSCLC) For more visit ResearchToPractice.com/5MJCMT2010
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Add your company logo here Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 AIR at UR Developing Best Practice Guidelines for Management of Rheumatoid Arthritis
More informationMeasuring and Mapping the Rheumatology Workforce in Canada An update for: Royal College- National Speciality Societies Human Resource for Health
Measuring and Mapping the Rheumatology Workforce in Canada An update for: Royal College- National Speciality Societies Human Resource for Health Dialogue June 2 nd 2017 Dr. Dianne Mosher The burden of
More informationKey ASCO Presentations Issue 2, Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases
Key ASCO Presentations Issue 2, 2010 Ipilimumab Monotherapy for Patients with Melanoma and Brain Metastases For more visit ResearchToPractice.com/5MJCMT2010 CME INFORMATION OVERVIEW OF ACTIVITY Each year,
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationPatient group: adults with a diagnosis of rheumatoid arthritis (RA)
eumusc.net HCQI RA 1 If a patient presents with suspected rheumatoid arthritis (RA) then he/she should be referred to and seen by a specialist (preferably a rheumatologist) for confirmation of diagnosis
More informationMeningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program
Meningococcal Education Program for Quebec Physicians: How Results Have Changed 2 Years after the Initial Program Marc H. Lebel, MD, FRCPC John Yaremko, MD, FRCPC Anne Dionne, MD, FRCPC Anne-Julie Gaudreau,
More informationKey ASH Presentations Issue 5, SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism
Key ASH Presentations Issue 5, 2012 SAVE-ONCO Trial of Thromboprophylactic Treatment with Semuloparin for Venous Thromboembolism CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology
More informationInsights from the Kaiser Permanente database
Insights from the Kaiser Permanente database Jashin J. Wu, M.D. Founding Director of Dermatology Research Director, Psoriasis Clinic Department of Dermatology Kaiser Permanente Los Angeles Medical Center
More informationOncology Pipeline Analytics
Oncology Pipeline Analytics Trials, Drug Classes, Indications, Correlations and Strategies Report Brochure O n c o l o g y P i p e l i n e A n a l y t i c s Greystone Research Associates is pleased to
More informationIdentifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations
University of Massachusetts Medical School escholarship@umms Open Access Articles Open Access Publications by UMMS Authors 4-26-2016 Identifying factors associated with concordance with the American College
More informationSecond Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer
Second Opinion An Interactive Case-Based Discussion on the Management of Early and Advanced Breast Cancer Proceedings from a CME Satellite Symposium at the 30 th Annual San Antonio Breast Cancer Symposium
More informationBest Practices in Managing Patients with Rheumatoid Arthritis. Cornerstone Health Care, P.A. Collecting and Measuring RA Data
Best Practices in Managing Patients with Rheumatoid Arthritis, P.A. Collecting and Measuring RA Data Organizational Profile opened in 1995 in High Point, North Carolina, as a multidisciplinary group of
More informationRVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma
RVD in Patients with High-Risk, Relapsed/Refractory Multiple Myeloma For more visit ResearchToPractice.com/5MJC CME INFORMATION OVERVIEW OF ACTIVITY Each year, thousands of clinicians and basic scientists
More informationChanging Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Saturday, October 27, 2018 7:00 AM - 3:45 PM Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer Program Director John V.
More informationRonald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden
Ronald F. van Vollenhoven Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute Stockholm, Sweden Disclosures Research Grants: AbbVie, Amgen, BMS, GSK, Pfizer, Roche,
More informationASCO s CLINICAL AFFAIRS DEPARTMENT
ASCO s CLINICAL AFFAIRS DEPARTMENT Walter Birch, Division Director Walter.Birch@asco.org New Clinical Affairs Department Helping practices survive and thrive today AND in the future Approved by the Board
More informationDLQI (ESTEEM
192 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis: Pruritus and DLQI Correlations at Week 16 (ESTEEM 1 and 2) Steven R. Feldman, MD, PhD 1 ; Diamant
More informationDevelopment of SLE among Possible SLE Patients Seen in Consultation: Long-Term Follow-Up. Disclosures. Background. Evidence-Based Medicine.
Development of SLE among Patients Seen in Consultation: Long-Term Follow-Up Abstract # 1699 May Al Daabil, MD Bonnie L. Bermas, MD Alexander Fine Hsun Tsao Patricia Ho Joseph F. Merola, MD Peter H. Schur,
More informationEthnic Minority RA Consortium (EMRAC)
Ethnic Minority RA Consortium (EMRAC) Yusuf Yazıcı, MD Assistant Professor of Medicine, New York University School of Medicine Director, Seligman Center for Advanced Therapeutics & Behçet Syndrome Evaluation,
More informationP4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling
P4081 Secukinumab skin clearance is associated with greater improvements in patient-reported pain, itching, and scaling Mark Lebwohl, 1 Andrew Blauvelt, 2 Matthias Augustin, 3 Yang Zhao, 4 Isabelle Gilloteau,
More informationImmunology and Immunotherapy 101 for the non-immunologist
Immunology and Immunotherapy 101 for the non-immunologist SITC Advances in Immunotherapy Seattle, WA 2016 Laura QM Chow Associate Professor University of Washington Associate Professor, Fred Hutchison
More informationDecision Making Across the Lifespan
40th Annual Meeting EXHIBIT AND SPONSORSHIP October 14-17, 2018 Fairmont The Queen Elizabeth Montreal, QC, Canada Decision Making Across the Lifespan 2018 OCTOBER 14th - 17th SMDM 390 Amwell Road, Suite
More informationSUNDAY, JAN 15 Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis
SUNDAY, JAN 15 Coordinating Care to Improve Outcomes in Patients with Psoriatic Arthritis National Doral, Miami, Florida 7:20 AM 8:20 AM, Ballroom B For more information about this no fee symposium visit
More informationTNF Inhibitors: Lessons From Immunogenicity
TNF Inhibitors: Lessons From Immunogenicity Edward Keystone, MD, FRCP(C) Professor of Medicine University of Toronto Toronto, Canada Edward Keystone, MD FRCP(C) Disclosures Sources of Funding for Research:
More informationPROFESSIONAL MEMBERSHIPS
June 2012 January 2014 October 2009 May 2012 Staff Rheumatologist, Diagnostic Clinic, Clearwater, FL Staff Rheumatologist, Arthritis Associates, Palm Harbor, FL 2008 2012 Co-Investigator, Arthritis Research
More informationRoles of Nurse Practitioners and Physician Assistants in Rheumatology Practices in the US
Roles of Nurse Practitioners and Physician Assistants in Rheumatology Practices in the US The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationKey ASH Presentations Issue 2, Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL)
Key ASH Presentations Issue 2, 2011 Lenalidomide in the Management of Chronic Lymphocytic Leukemia (CLL) For more visit ResearchToPractice.com/5MJCASH2011 CME INFORMATION OVERVIEW OF ACTIVITY The annual
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 Ochsner Best Practices in Managing patients with Rheumatoid Arthritis 2 Medical Group Profile When was your
More informationAssessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study
Assessment of Quality of Life Using Skindex-16 in Patients With Locally Advanced Basal Cell Carcinoma Treated With Vismodegib in the STEVIE Study Jean-Jacques Grob, 1 Karen Bartley, 2 Rainer Kunstfeld,
More informationApproximately 3% of the US adult population,
Disease Burden and Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Results From National Psoriasis Foundation Panel Surveys Emily Edson-Heredia, MPH; Baojin Zhu, PhD;
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationS1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer
POST-SABCS Issue 1, 2013 S1207 Trial of Adjuvant Endocrine Therapy with or without Everolimus for High-Risk, Hormone Receptor-Positive, HER2-Negative Breast Cancer For more visit ResearchToPractice.com/5MJCSABCS2013
More informationEconomic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States
1142 Economic Evaluation of Apremilast in the Treatment of Moderate to Severe Psoriasis in the United States Tom Tencer, PhD 1 ; Zoe Clancy, PharmD, MS 1 ; Vidya Damera, MS 2 ; Frank Zhang MD, MPH 1 ;
More informationFor Rheumatoid Arthritis
For Rheumatoid Arthritis APRIL 2017 NOTICE: On April 14, 2017 the FDA issued a complete response letter for baricitinib indicating that the FDA is unable to approve the application in its current form
More informationEHR SOFTWARE COMPARISON
EHR SOFTWARE COMPARISON C M CONVERTED MEDIA WHY NOT CREATE YOUR OWN COMPARISON? With our free comparison engine you can build your own side-by-side comparison of leading EHR solutions. Narrow down your
More informationActivity and Endoscopic measures : Crohn s disease. Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York
Activity and Endoscopic measures : Crohn s disease Jean-Frederic COLOMBEL Justin Cote-Daigneault Icahn Medical School at Mount Sinai, New York J-F Colombel has served as consultant or advisory board member
More informationCLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS
CLINICAL GUIDELINES COMMITTEE September 9-10, 2014 DISCLOSURE OF INTERESTS NAME Financial INTERESTS Non-Financial Thomas Denberg, MD, PhD, FACP, Chair Michael J. Barry, MD, MACP Indicate Employment: Carilion
More informationFaculty. Course Directors. Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist
Faculty Course Directors Liza Blumenfeld, MA, CCC-SLP, BCS-S UC San Diego Health - Speech-Language Pathologist Non-financial Disclosure: Developer of Swallow RehApp Joseph Califano, MD UC San Diego Health
More informationHoarding. Exhibitor, Sponsor, and Advertiser Brochure. Thursday - April 26, 2012 Friday - April 27, Westin San Francisco Airport Hotel
Collaborate Collaborate with other community partners Empower Empower yourself or others with hoarding and cluttering challenges Research Engage in discussions about new cutting edge clinical and field
More informationTHINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd
THINC-it: what is it? John Harrison Alzheimer Center, VU University Medical Center, West London Mental Health Trust, Metis Cognition Ltd Disclosures Associate Professor in the Alzheimer Center at the VU
More informationRheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie
1 Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 13-15, 2014 HealthCare Partners Optimizing Value of RA Care 2 Medical Group Profile Established in 1993 as a partnership
More informationUnderstanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies
1 Understanding the U.S. Preventive Services Task Force and its Conflicts of Interest Policies Quyen Ngo-Metzger, MD, MPH Scientific Director, USPSTF Program Agency for Healthcare Research and Quality
More informationRETIRED. Maximum Drug Dose Policy
RETIRED DRUG POLICY Policy Number 2017D0034A Maximum Drug Dose Policy Annual Approval Date 3/1/2017 Approved By UnitedHealthcare National Pharmacy & Therapeutics Committee United Healthcare Community Plan
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationCase Study: Physician and Patient-Facing Medical Education APPs. Sandeep Pulim, MD Chief Medical Information Officer
Case Study: Physician and Patient-Facing Medical Education APPs Sandeep Pulim, MD Chief Medical Information Officer Quality IME Collaborating for Patient Care Commercial Supporter Medical Education Provider
More informationPhysiotherapy and Biokinetics Activity for 2015
Physiotherapy and Biokinetics Activity for 2015 Activity No: D6 (15) General Topic: Fibromyalgia Topics: Fibromyalgia Guidelines Trigger Changes for FPs Resistance, Aerobic Training May Reduce Pain in
More informationPragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA
Pragmatic Trial Design to Study Health Policy Interventions: Lessons Learned from ARTEMIS Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA Associate Professor of Medicine, Duke University Director of Health Services
More informationPatient Engagement Improving Outcomes for Patients with Rheumatoid Arthritis
Patient Engagement Improving Outcomes for Patients with Rheumatoid Arthritis Ryan Antolini, M.D. Timothy Gensler, M.D. John Janas, M.D. Presenters Denver Arthritis Clinic Ryan Antolini, M.D. Board Certified
More informationValutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND. Workshop Nazionale CISAI Lecco 20 Marzo 2015
Valutazione dei disturbi neurocognitivi e invecchiamento: non solo HAND Workshop Nazionale CISAI Lecco 20 Marzo 2015 Paola Cinque Dipartimento di Malattie Infettive Istituto Scientifico San Raffaele, Milano
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationFirst Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the LAPIS-PSO Study: An Interim Analysis
5137 First Real-World Insights on Apremilast Therapy for Patients With Plaque Psoriasis From the Study: An Interim Analysis Kristian Reich, MD 1 ; Stefanie Bomas, MD 2 ; Bernhard Korge, MD 3 ; Maria Manasterski,
More informationRheumatoid Arthritis Learning Collaborative
Rheumatoid Arthritis Learning Collaborative Sponsored by AMGF and AbbVie August 12 14, 2015 USMD Rheumatoid Arthritis Collaborative Medical Group Profile USMD Health System: May 7, 2010 Medical Clinic
More informationTHE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES
THE CORPORATE REPUTATION OF PHARMA 2015 THE PERSPECTIVE OF 139 PATIENT GROUPS with an interest in DIABETES PUBLISHED AUGUST 2016 There is growing distrust of pharma in light of several recent and dramatic
More informationDrug Class Review Targeted Immune Modulators
Drug Class Review Targeted Immune Modulators Final Update 5 Report June 2016 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationJune 4, Via Electronic Transmission
June 4, 2008 Via Electronic Transmission Dr. Drew Gilpin Faust President Harvard University Massachusetts Hall Cambridge, MA 02138 Dr. Peter L. Slavin President Massachusetts General Hospital (Partners
More informationVasculitis Update 2017
June 24, 2017 Chicago, Illinois Sponsored by: Office of Continuing Medical Education Division of Rheumatology Vasculitis Clinical Research Consortium Vasculitis Foundation Page 2 About At Northwestern
More informationNitin S. Damle, Disclosure of Interests American College of Physicians
Nitin S. Damle, Dr. Damle discloses the following interests: South County Internal Medicine Inc (null) Employment: Grants/Contracts: null (null) Speaker's Bureaus: Executive Boards: Consulting/Honoraria:
More informationORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab
More informationKEYNOTE PRESENTATION. Edward A Stadtmauer, MD and Patricia Mangan, MSN, CRNP
AGENDA Access Pre/Post Tests and Presentations: PennMedicine.org/Abramson/BloodCME Password: Blood2018 (case sensitive) For Free Wi-Fi use HHonors Promotion Code: phlph2218 7:30 am Registration and Continental
More informationModels of care for management of HCV among PWID. Philip Bruggmann Switzerland
Models of care for management of HCV among PWID Philip Bruggmann Switzerland Disclosures Speaker and advisory board fees from Merck, Abbvie, Gilead, Janssen and BMS Financial support for projects of Arud
More informationPfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients
Pfizer Independent Grants for Learning & Change Request for Proposals (RFP) Rheumatoid Arthritis Mono- and Combination DMARD Therapy in RA Patients I. Background The mission of Pfizer Independent Grants
More informationThe next-generation, evidence-based clinical information resource. designed to optimize time to answer.
The next-generation, evidence-based clinical information resource designed to optimize time to answer. Trust is the bottom line. Physicians create DynaMed Plus content. DynaMed Plus EVIDENCE-BASED METHODOLOGY
More informationDRAFT SLIDES. Michael Huss Child and Adolescent Psychiatry, Johannes Gutenberg University Mainz, Mainz, Germany
DRAFT SLIDES Separating efficacy and sedative effects of guanfacine extended release in children and adolescents with ADHD from four randomized, controlled, phase 3 clinical trials Michael Huss Child and
More informationAre Immune Modulators Really Needed to Cure HBV infection?
Are Immune Modulators Really Needed to Cure HBV infection? Harry L.A. Janssen Francis Family Chair of Hepatology Director Toronto Centre for Liver Disease University Health Network University of Toronto,
More informationGeneral Internal Medicine. General Internal Medicine Profile
Updated March 2018 1 Click on any of the contents below to navigate to the slide. Please click the home icon located at the top right of each slide to return to the table of contents slide. TABLE OF CONTENTS
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationPREVENTING COLLATERAL DAMAGE IN THE INFLAMMATORY BOWEL DISEASE PATIENT: USING DISEASE ASSESSMENT AND PROGNOSTIC FACTORS TO OPTIMISE CLINICAL OUTCOMES
PREVENTING COLLATERAL DAMAGE IN THE INFLAMMATORY BOWEL DISEASE PATIENT: USING DISEASE ASSESSMENT AND PROGNOSTIC FACTORS TO OPTIMISE CLINICAL OUTCOMES This symposium took place on the 17 th October 2016,
More informationTargeted Agent and Profiling Utilization Registry
Targeted Agent and Profiling Utilization Registry Richard L. Schilsky, MD, FACP, FASCO Senior Vice President and Chief Medical Officer American Society of Clinical Oncology Disclosure Information Richard
More informationMedicare Part C Medical Coverage Policy
Step Therapy: Part B Medications Origination: December 19, 2018 Review Date: December 19, 2018 Next Review: December 2020 Medicare Part C Medical Coverage Policy DESCRIPTION OF PROCEDURE SERVICE Step Therapy
More information290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3
290O - Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: results from MONALEESA-3 Presentation Number: 290O Lecture Time: 11:18-11:33 Speakers: Peter
More informationNew Prognostic Markers in Acute Myeloid Leukemia (AML)
New Prognostic Markers in Acute Myeloid Leukemia (AML) For more visit ResearchToPractice.com/5MJCMDSAML CME INFORMATION OVERVIEW OF ACTIVITY Acute myeloid leukemia (AML) and the myelodysplastic syndromes
More informationImpact of WRVU Changes. Allowed Charges (Millions)
Key Financial and Operational s from the Proposed 2018 PFS Rule: The 2018 Physician Fee Schedule (PFS) proposed rule was made available on July 13, 2018. A detailed summary of the rule will be available
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Most people with psoriasis or rosacea are not being treated: a large population study Permalink https://escholarship.org/uc/item/4nc3p4q2 Journal Dermatology Online
More information